Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
Japan’s proposed public-private council for the biopharmaceutical ecosystem set to launch around this summer must put a pro-innovation drug pricing reform at the top of its agenda, with clear objectives and follow-ups, Simone Thomsen, the local chief of the Pharmaceutical…
To read the full story
Related Article
- Japan Sets June 26 for First Meeting of Public-Private Council for Biopharmaceutical Innovation
June 24, 2025
- Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
- PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
December 26, 2024
- PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
November 28, 2024
ORGANIZATION
- JPMA Exec Frets over Material Cost Surge amid Middle East Crisis
April 17, 2026
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…